Bernard Arnault, chairman and CEO of LVMH, credited strong brand appeal, consumer attraction to artisanal products and simple business strategy with prompting the growth.
Moreover, treatment with Eylea requires fewer patient visits, prompting analysts to predict that Genentech will have to look twice, pun intended, at its strategy.